Cannabis update: Anxiety disorders and post-traumatic stress disorder



doi: 10.1097/JXX.0000000000000864.


Online ahead of print.

Affiliations

Item in Clipboard

Amy L Haycraft.


J Am Assoc Nurse Pract.


.

Abstract

The development of anxiety disorders and post-traumatic stress disorder (PTSD) is complex. Both delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are of potential therapeutic use. Evidence suggests that cannabis has a beneficial effect on neural circuitry involved in fear regulation. In the United States, cannabis is considered either medical or recreational and can contain pure THC or CBD or any combination thereof. The numerous cannabis compounds of various administration routes, with variable pharmacokinetics, further affect the cannabis conundrum. Despite being federally unregulated, medical cannabis has received increased attention socially, and at present, 37 states, four territories, and the District of Columbia have legalized medical cannabis for use in specific health conditions. Patients are increasingly inquiring about cannabis, and clinicians must educate themselves with reliable cannabinoid information for patient education. In adults with anxiety disorders and PTSD, evidence supports a relatively safe profile for medical cannabis; however, conclusive scientific evidential support of its therapeutic properties is limited, resulting in a lack of standardization and Food and Drug Administration approval.

Conflict of interest statement

Competing interests: The author reports no conflicts of interest.

References

    1. Alexandra Kredlow M., Fenster R. J., Laurent E. S., Ressler K. J., Phelps E. A. (2022). Prefrontal cortex, amygdala, and threat processing: Implications for PTSD. Neuropsychopharmacology, 47(1), 247–259. https://doi.org/10.1038/s41386-021-01155-7



      DOI

    1. American Psychiatric Association (2013). Diagnostic and statistical manual of mental disorders (5th ed) https://doi.org/10.1176/appi.books.9780890425596

    1. Baethge C., Hennen J., Khalsa H. M. K., Salvatore P., Tohen M., Baldessarini R. J. (2008). Sequencing of substance use and affective morbidity in 166 first-episode bipolar I disorder patients. Bipolar Disorders, 10(6), 738–741. https://doi.org./10.1111/j.1399-5618.2007.00575.x



      DOI

    1. Barry T. J., Murray L., Fearon P., Moutsiana C., Johnstone T., Halligan S. L. (2017). Amygdala volume and hypothalamic-pituitary-adrenal axis reactivity to social stress. Psychoneuroendocrinology, 85, 96–99. https://doi.org/10.1016/j.psyneuen.2017.07.487



      DOI

    1. Bonn-Miller M. O., Sisley S., Riggs P., Yazar-Klosinski B., Wang J. B., Loflin M. J. E., Shechet B., Hennigan C., Matthews R., Emerson A., Doblin R. (2021). The short-term impact of 3 smoked cannabis preparations versus placebo on PTSD symptoms: A randomized cross-over clinical trial. Plos One, 16(3), e0246990. https://doi.org/10.1371/journal.pone.0246990



      DOI

Read more here: Source link

Leave a Reply

Your email address will not be published. Required fields are marked *